AbstractThe dataset provided here contains the efforts of independent data aggregation, quality control, and visualization of the University of Arizona (UofA) COVID-19 testing programs for the 2019 novel Coronavirus pandemic. The dataset is provided in the form of machine-readable tables in comma-separated value (.csv) and Microsoft Excel (.xlsx) formats.Additional InformationAs part of the UofA response to the 2019-20 Coronavirus pandemic, testing was conducted on students, staff, and faculty prior to start of the academic year and throughout the school year. These testings were done at the UofA Campus Health Center and through their instance program called "Test All Test Smart" (TATS). These tests identify active cases of SARS-nCoV-2 infections using the reverse transcription polymerase chain reaction (RT-PCR) test and the Antigen test. Because the Antigen test provided more rapid diagnosis, it was greatly used three weeks prior to the start of the Fall semester and throughout the academic year.As these tests were occurring, results were provided on the COVID-19 websites. First, beginning in early March, the Campus Health Alerts website reported the total number of positive cases. Later, numbers were provided for the total number of tests (March 12 and thereafter). According to the website, these numbers were updated daily for positive cases and weekly for total tests. These numbers were reported until early September where they were then included in the reporting for the TATS program.For the TATS program, numbers were provided through the UofA COVID-19 Update website. Initially on August 21, the numbers provided were the total number (July 31 and thereafter) of tests and positive cases. Later (August 25), additional information was provided where both PCR and Antigen testings were available. Here, the daily numbers were also included. On September 3, this website then provided both the Campus Health and TATS data. Here, PCR and Antigen were combined and referred to as "Total", and daily and cumulative numbers were provided.At this time, no official data dashboard was available until September 16, and aside from the information provided on these websites, the full dataset was not made publicly available. As such, the authors of this dataset independently aggregated data from multiple sources. These data were made publicly available through a Google Sheet with graphical illustration provided through the spreadsheet and on social media. The goal of providing the data and illustrations publicly was to provide factual information and to understand the infection rate of SARS-nCoV-2 in the UofA community.Because of differences in reported data between Campus Health and the TATS program, the dataset provides Campus Health numbers on September 3 and thereafter. TATS numbers are provided beginning on August 14, 2020.Description of Dataset ContentThe following terms are used in describing the dataset.1. "Report Date" is the date and time in which the website was updated to reflect the new numbers2. "Test Date" is to the date of testing/sample collection3. "Total" is the combination of Campus Health and TATS numbers4. "Daily" is to the new data associated with the Test Date5. "To Date (07/31--)" provides the cumulative numbers from 07/31 and thereafter6. "Sources" provides the source of information. The number prior to the colon refers to the number of sources. Here, "UACU" refers to the UA COVID-19 Update page, and "UARB" refers to the UA Weekly Re-Entry Briefing. "SS" and "WBM" refers to screenshot (manually acquired) and "Wayback Machine" (see Reference section for links) with initials provided to indicate which author recorded the values. These screenshots are available in the records.zip file.The dataset is distinguished where available by the testing program and the methods of testing. Where data are not available, calculations are made to fill in missing data (e.g., extrapolating backwards on the total number of tests based on daily numbers that are deemed reliable). Where errors are found (by comparing to previous numbers), those are reported on the above Google Sheet with specifics noted.For inquiries regarding the contents of this dataset, please contact the Corresponding Author listed in the README.txt file. Administrative inquiries (e.g., removal requests, trouble downloading, etc.) can be directed to data-management@arizona.edu

This item has been archived. It is no longer being updated.For current COVID-19 cases data updates, please see the COVID-19 Cases Per 100,000 by Zip Code dashboard, which shows the COVID-19 case rate per 100,000 population by week for each zip code and is supported by the weekly release of data from the Maricopa County Department of Public Health (MCDPH) https://data.tempe.gov/datasets/covid-19-case-indicators/explore.--------As of 3/2/2022 the Arizona Department of Health Services has shifted to a weekly update schedule. We've adjusted our process to update every Wednesday afternoon.This table provides a weekly log of confirmed COVID-19 cases by Zip Code. Data are provided by the Arizona Department of Health Services (ADHS). Data Source: Arizona Department of Health Services (AZDHS) daily COVID-19 report by zip code (https://adhsgis.maps.arcgis.com/apps/opsdashboard/index.html#/84b7f701060641ca8bd9ea0717790906). Daily Change is calculated by taking the current day’s case value for a given Postal Code and subtracting the prior day’s value. This resulting value is the Daily Change. Based on reporting from ADHS Daily Change may be a positive or negative number or 0 if no change has been reported. Moving Average is calculated by summing the current day’s case count with the prior 6 days’ cases for a given Postal Code and dividing by 7.Arizona Department of Health Services (AZDHS) data are scheduled for daily updates at 9:00 AM (COVID-19 cases) and 12:00 PM (COVID-19 vaccinations), but the times when the AZDHS releases that days COVID-19 cases and vaccinations may vary. City of Tempe data are updated each afternoon at 3:00 PM to allow for possible AZDHS delays. When there are AZDHS delays in updating the daily data, dashboard data updates may be delayed by 24 hours. The charts and daily values list can be used to confirm the date of the most recent counts on the COVID-19 cases and vaccinations dashboards. If data are not released by the time of the scheduled daily dashboard refresh, that day's values may appear on the dashboard as an addition to the next day's value.Additional InformationSource: Arizona Department of Health Services (AZDHS) daily COVID-19 report by zip code (https://adhsgis.maps.arcgis.com/apps/opsdashboard/index.html#/84b7f701060641ca8bd9ea0717790906)Contact (author): n/aContact E-Mail (author): n/aContact (maintainer): City of Tempe Open Data TeamContact E-Mail (maintainer): data@tempe.govData Source Type: TablePreparation Method: Data are exposed via ArcGIS Server and its REST API.Publish Frequency: DailyPublish Method: Data are downloaded each afternoon once ADHS updates its public API. Data are transformed and appended to a table in Tempe’s Enterprise GIS.Data Dictionary

Demographic characteristics of 1,900 Arizona CoVHORT participants aged 18 years or older that enrolled in the study between May 28, 2020, and April 2, 2022, and reported a positive result from laboratory conducted SARS-CoV-2 diagnostic test prior to April 2, 2022.

Cumulation of the weekly release of COVID-19 data for Maricopa County by City. Includes PCR Test Percent Positivity as viewed on the Maricopa County School Reopening Dashboard map by week. For more information about the data, visit: https://www.maricopa.gov/5594/School-Metrics.

Wastewater collection areas are comprised of merged sewage drainage basins that flow to a shared testing location for the COVID-19 wastewater study. The collection area polygons are published with related wastewater testing data, which are provided by scientists from Arizona State University's Biodesign Institute.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19. People infected with SARS-CoV-2 excrete the virus in their feces in a process known as “shedding”. The municipal wastewater treatment system (sewage system) collects and aggregates these bathroom contributions across communities. Tempe wastewater samples are collected downstream of a community and the samples are brought to the ASU lab to analyze for the virus. Analysis is based on the genetic material inside the virus. This dashboard focuses on the genome copies per liter. The absence of a value in a chart indicates that either no samples were collected or that samples are still being analyzed. A value of 5,000 represents samples that are below detection or reporting limits for the test being used. Note of Caution:The influence of this data on community health decisions in the future is unknown. Data collection is being used to depict overall weekly trends and should not be interpreted without a holistic assessment of public health data. The purpose of this weekly data is to support research as well as to identify overall trends of the genome copies in each liter of wastewater per collection area. In the future these trend data could be used alongside other authoritative data, including the number of daily new confirmed cases in Tempe published by the Arizona Department of Health and data documenting the state and local interventions (i.e. social distancing, closures and safe openings). The numeric values of the results should not be viewed as actionable right now; they represent one potentially helpful piece of information among various data sources.We share this information with the public with the disclaimer that only the future can tell how much “diagnostic value” we can and should attribute to the numeric measurements we obtain from the sewer. However, what we measure, the COVID-19-related RNA in wastewater, we know is real and we share that info with our community.In the Tempe COVID -19 Wastewater Results Dashboard, please note:These data illustrate a trend of the signal of the weekly average of COVID-19 genome copies per liter of wastewater in Tempe's sewage. The dashboard and collection area map do not depict the number of individuals infected. Each collection area includes at least one sampling location, which collects wastewater from across the collection area. It does not reflect the specific location where the deposit occurs.While testing can successfully quantify the results, research has not yet determined the relationship between these genome values and the number of people who are positive for COVID-19 in the community.The quantity of RNA detected in sewage is real; the interpretation of that signal and its implication for public health is ongoing research. Currently, there is not a baseline for determining a strong or weak signal.The shedding rate and shedding duration for individuals, both symptomatic and asymptomatic, is still unknown.Data are shared as the testing results become available. As results may not be released at the same time, testing results for each area may not yet be seen for a given day or week. The dashboard presents the weekly averages. Data are collected from 2-7 days per week. The quantifiable level of 5,000 copies per liter is the lowest amount measurable with current testing. Results that are below the quantifiable level of 5,000 copies per liter do not suggest the absence of the virus in the collection area. It is possible to have results below the quantifiable level of 5,000 on one day/week and then have a greater signal on a subsequent day/week.For Collection Area 1, Tempe's wastewater co-mingles with wastewater from a regional sewage line. Tempe's sewage makes up the majority of Collection Area 1 samples. After the collection period of April 7-24, 2020, Collection Area 1 samples include only Tempe wastewater.For Collection Area 3, Tempe's wastewater co-mingles with wastewater from a regional sewage line. For analysis and reporting, Tempe’s wastewater is separated from regional sewage. This operations dashboard is used in an associated story map Fighting Coronavirus/COVID-19 with Public Health Data https://storymaps.arcgis.com/stories/e6a45aad50c24e22b7285412d2d6ff2a about the COVID-19 wastewater testing project. This operations dashboard also support's the main Tempe Wastewater BioIntel Program hub site https://wastewater.tempe.gov/.

Self-reported symptoms of COVID-19 positive participants experiencing PASC at 30 or more days of follow-up from 28 May 2020–24 February 2021 in Arizona.

Updated: As of 7/3/2021 the Arizona Department of Health Services is no longer updated its vaccination data. This item has been deprecated as a result.This table provides a daily log of confirmed COVID-19 vaccinations by Zip Code for the state of Arizona. Data are provided by the Arizona Department of Health Services (ADHS). Data Source: Arizona Department of Health Services (AZDHS) daily COVID-19 vaccinations report by zip code (https://experience.arcgis.com/experience/bcf70a0f5cac4262a411166dbcac9053). Daily Change is calculated by taking the current day’s vaccination value for a given Postal Code and subtracting the prior day’s value. This resulting value is the Daily Change. Based on reporting from ADHS Daily Change may be a positive or negative number or 0 if no change has been reported. Arizona Department of Health Services (AZDHS) data are scheduled for daily updates at 9:00 AM (COVID-19 cases) and 12:00 PM (COVID-19 vaccinations), but the times when the AZDHS releases that days COVID-19 cases and vaccinations may vary. City of Tempe data are updated each afternoon at 3:00 PM to allow for possible AZDHS delays. When there are AZDHS delays in updating the daily data, dashboard data updates may be delayed by 24 hours. The charts and daily values list can be used to confirm the date of the most recent counts on the COVID-19 cases and vaccinations dashboards. If data are not released by the time of the scheduled daily dashboard refresh, that day's values may appear on the dashboard as an addition to the next day's value.---------------------------------------------------Please also see the following items for up-to-date COVID-19 vaccination data:COVID-19 Vaccination Rates by Zip Code (Maricopa County)https://data.tempe.gov/datasets/covid-19-vaccination-rates-by-zip-code-maricopa-county/exploreCOVID-19 Vaccination Rates by City (Maricopa County)https://data.tempe.gov/datasets/covid-19-vaccination-rates-by-city-maricopa-county/explore ---------------------------------------------------Additional InformationSource: Arizona Department of Health Services (AZDHS) daily COVID-19 vaccinations report by zip code (https://experience.arcgis.com/experience/bcf70a0f5cac4262a411166dbcac9053)Contact (author): n/aContact E-Mail (author): n/aContact (maintainer): City of Tempe Open Data TeamContact E-Mail (maintainer): data@tempe.govData Source Type: TablePreparation Method: Data are exposed via ArcGIS Server and its REST API.Publish Frequency: DailyPublish Method: Data are downloaded each afternoon once ADHS updates its public API. Data are transformed and appended to a table in Tempe’s Enterprise GIS.Data Dictionary

SB: AZ: COVID-19 Impact: Moderate Positive Effect data was reported at 5.700 % in 11 Apr 2022. This records a decrease from the previous number of 8.400 % for 04 Apr 2022. SB: AZ: COVID-19 Impact: Moderate Positive Effect data is updated weekly, averaging 8.000 % from Nov 2021 (Median) to 11 Apr 2022, with 18 observations. The data reached an all-time high of 10.100 % in 22 Nov 2021 and a record low of 5.700 % in 11 Apr 2022. SB: AZ: COVID-19 Impact: Moderate Positive Effect data remains active status in CEIC and is reported by U.S. Census Bureau. The data is categorized under Global Database’s United States – Table US.S: Small Business Pulse Survey: by State: West Region: Weekly, Beg Monday (Discontinued).

Cumulation of the weekly release of COVID-19 data for Maricopa County by Zip Code. Includes PCR Test Percent Positivity as viewed on the Maricopa County School Reopening Dashboard map by week. For more information about the data, visit: https://www.maricopa.gov/5594/School-Metrics.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

The purpose of this data collection was to examine the relationship between drug use and pretrial misconduct in Pima and Maricopa counties in Arizona. Data assess the effectiveness of Arizona pretrial services, which were designed to monitor those defendants who tested positive for selected drugs. The collection includes variables for drugs such as marijuana and cocaine, previous criminal history, results of urinalysis testing, pretrial misconduct, and drug monitoring. Demographic information includes defendant's sex, ethnicity, age, marital status, employment, and last grade completed.

In nature, rabies virus (RABV; genus Lyssavirus, family Rhabdoviridae) represents an assemblage of phylogenetic lineages, associated with specific mammalian host species. Although it is generally accepted that RABV evolved originally in bats and further shifted to carnivores, mechanisms of such host shifts are poorly understood, and examples are rarely present in surveillance data. Outbreaks in carnivores caused by a RABV variant, associated with big brown bats, occurred repeatedly during 2001–2009 in the Flagstaff area of Arizona. After each outbreak, extensive control campaigns were undertaken, with no reports of further rabies cases in carnivores for the next several years. However, questions remained whether all outbreaks were caused by a single introduction and further perpetuation of bat RABV in carnivore populations, or each outbreak was caused by an independent introduction of a bat virus. Another question of concern was related to adaptive changes in the RABV genome associated with host shifts. To address these questions, we sequenced and analyzed 66 complete and 20 nearly complete RABV genomes, including those from the Flagstaff area and other similar outbreaks in carnivores, caused by bat RABVs, and representatives of the major RABV lineages circulating in North America and worldwide. Phylogenetic analysis demonstrated that each Flagstaff outbreak was caused by an independent introduction of bat RABV into populations of carnivores. Positive selection analysis confirmed the absence of post-shift changes in RABV genes. In contrast, convergent evolution analysis demonstrated several amino acids in the N, P, G and L proteins, which might be significant for pre-adaptation of bat viruses to cause effective infection in carnivores. The substitution S/T242 in the viral glycoprotein is of particular merit, as a similar substitution was suggested for pathogenicity of Nishigahara RABV strain. Roles of the amino acid changes, detected in our study, require additional investigations, using reverse genetics and other approaches.

This data collection represents a combined experimental evaluation of a drug court program, implemented in 1992 in cooperation with the Maricopa County Adult Probation Department, in comparison to standard probation with different levels of drug testing. The experiment's objective was to compare the drug use and criminal behavior of probationers assigned to four alternative regimes or tracks: (1) standard probation, but no drug testing, (2) standard probation with random monthly drug tests, (3) standard probation with testing scheduled twice a week, and (4) drug court, an integrated program of drug testing, treatment, and sanctions that utilized a carefully structured set of rewards and punishments. The experiment was limited to first-time felony offenders convicted of drug possession or use (not sales) and sentenced to a term of three years' probation. A total of 630 probationers from Maricopa County were randomly assigned to one of the four experimental regimes and tracked for a 12-month period. Data collection efforts included: (1) background information on each participant, (2) process information on the characteristics of supervision and services provided under each experimental condition, and (3) follow-up data on subsequent drug use, crime, and pro-social activities for 12 full months. Background Data (Part 1) include demographic variables such as race, sex, education, marital status, living arrangements, and employment history. In addition, there are variables on prior drug use and abuse, drug treatment, criminal histories as both a juvenile and an adult, and risk and need assessment scores. Other variables include the results of drug testing and any sanctions taken for a positive result (Part 2), new arrests while on probation and corresponding disposition and conviction (Part 3), and technical violations and any actions taken for these violations (Part 4). For probationers assigned to drug court (Part 5) there are variables measuring probationers' status, probation recommendations, and judges' decisions at 11 different progress assessments. The follow-up information (Parts 6-8) includes monthly data on the status of the probationer, the number of face-to-face office contacts, phone contacts, work/school contacts, and community contacts, collateral checks, employment/school verification, counseling sessions, alcohol tests, drug tests, substance abuse treatment, the number of hours the probationer spent job hunting, in educational training, in vocational training, and in community service, the number of days employed full- and part-time, and the amount of earnings, fines paid, restitution paid, and fees paid.